SG11202003452XA - Dantrolene prodrugs and methods of their use - Google Patents
Dantrolene prodrugs and methods of their useInfo
- Publication number
- SG11202003452XA SG11202003452XA SG11202003452XA SG11202003452XA SG11202003452XA SG 11202003452X A SG11202003452X A SG 11202003452XA SG 11202003452X A SG11202003452X A SG 11202003452XA SG 11202003452X A SG11202003452X A SG 11202003452XA SG 11202003452X A SG11202003452X A SG 11202003452XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- dantrolene
- prodrugs
- dantrolene prodrugs
- Prior art date
Links
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 title 1
- 229960001987 dantrolene Drugs 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575124P | 2017-10-20 | 2017-10-20 | |
| US201862674422P | 2018-05-21 | 2018-05-21 | |
| PCT/US2018/056713 WO2019079721A1 (en) | 2017-10-20 | 2018-10-19 | DANTROLENE PRODRUGS AND METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003452XA true SG11202003452XA (en) | 2020-05-28 |
Family
ID=64277793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003452XA SG11202003452XA (en) | 2017-10-20 | 2018-10-19 | Dantrolene prodrugs and methods of their use |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11352347B2 (https=) |
| EP (2) | EP3697779B1 (https=) |
| JP (2) | JP7252963B2 (https=) |
| KR (1) | KR102652642B1 (https=) |
| CN (1) | CN111344286A (https=) |
| AU (2) | AU2018351494C1 (https=) |
| BR (1) | BR112020007858A2 (https=) |
| CA (1) | CA3079558A1 (https=) |
| CO (1) | CO2020006193A2 (https=) |
| ES (1) | ES3016835T3 (https=) |
| IL (1) | IL274045B2 (https=) |
| MA (1) | MA50403A (https=) |
| MX (2) | MX2020003400A (https=) |
| MY (1) | MY201417A (https=) |
| NZ (1) | NZ763377A (https=) |
| SG (1) | SG11202003452XA (https=) |
| UA (1) | UA127738C2 (https=) |
| WO (1) | WO2019079721A1 (https=) |
| ZA (1) | ZA202002779B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY201417A (en) * | 2017-10-20 | 2024-02-21 | Eagle Res Labs Limited | Dantrolene prodrugs and methods of their use |
| US12246028B2 (en) * | 2018-11-27 | 2025-03-11 | Eagle Research Labs Limited | Use of dantrolene and dantrolene prodrugs to treat radiation exposure |
| EP3771711A1 (en) | 2019-07-29 | 2021-02-03 | Bayer Animal Health GmbH | Pyrazole derivatives for controlling arthropods |
| AU2021254415A1 (en) | 2020-04-10 | 2022-10-20 | Eagle Pharmaceuticals, Inc. | Methods of treating Severe Acute Respiratory Syndrome |
| US12605364B2 (en) | 2020-04-10 | 2026-04-21 | Eagle Pharmaceuticals, Inc. | Methods of treating SARS-CoV-2 infections |
| WO2021207446A1 (en) | 2020-04-10 | 2021-10-14 | Eagle Pharmaceuticals, Inc. | Methods of treating viral infections |
| EP4132519A1 (en) | 2020-04-10 | 2023-02-15 | Eagle Pharmaceuticals, Inc. | Methods of treating coronavirus infections |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415821A (en) | 1965-09-07 | 1968-12-10 | Norwich Pharma Co | 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones |
| US4137402A (en) | 1978-03-30 | 1979-01-30 | Morton-Norwich Products, Inc. | Quaternary ammonium salts of dantrolene and clodanolene |
| US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| TWI369982B (en) | 2007-01-11 | 2012-08-11 | Xenoport Inc | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
| EP2583670A1 (en) * | 2007-10-09 | 2013-04-24 | US Worldmeds LLC | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| WO2009067175A2 (en) | 2007-11-16 | 2009-05-28 | Nektar Therapeutics Al, Corporation | Oligomer-dantrolene conjugates and related compounds |
| US20090306163A1 (en) | 2008-06-10 | 2009-12-10 | Pamela Renee Lipkin | Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling |
| FR2944525B1 (fr) | 2009-04-17 | 2011-06-24 | Ipsen Pharma Sas | Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament |
| ES2592518T3 (es) | 2011-10-13 | 2016-11-30 | Merck Sharp & Dohme Corp. | Antagonistas del receptor de mineralocorticoides |
| US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| EP2968229B1 (en) | 2013-03-15 | 2019-12-04 | Rosalind Franklin University of Medicine and Science | Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| WO2014191837A2 (en) | 2013-05-06 | 2014-12-04 | University Health Network | Methods of administering dantrolene for the acute treatment of cardiac arrhythmias |
| US9433608B2 (en) | 2013-05-08 | 2016-09-06 | Howard University | Compositions and method for treatment of ischemic neuronal reperfusion injury |
| HUP1300720A2 (hu) | 2013-12-12 | 2015-06-29 | Univ Szegedi | Gyógyászati készítmények sebgyógyulás elõsegítésére |
| JPWO2015182625A1 (ja) | 2014-05-26 | 2017-06-08 | 国立大学法人京都大学 | Ｒａｓ活性阻害薬及びその用途 |
| WO2016077706A1 (en) | 2014-11-13 | 2016-05-19 | Washington University | Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders |
| JP7409772B2 (ja) | 2015-10-20 | 2024-01-09 | スぺファーム アクチェンゲゼルシャフト | ダントロレンを含む水性組成物 |
| MY201417A (en) * | 2017-10-20 | 2024-02-21 | Eagle Res Labs Limited | Dantrolene prodrugs and methods of their use |
| SE542780C2 (en) | 2018-09-15 | 2020-07-07 | Coloreel Group AB | A system and method for in-line treatment of thread |
-
2018
- 2018-10-19 MY MYPI2020001973A patent/MY201417A/en unknown
- 2018-10-19 WO PCT/US2018/056713 patent/WO2019079721A1/en not_active Ceased
- 2018-10-19 MA MA050403A patent/MA50403A/fr unknown
- 2018-10-19 BR BR112020007858-1A patent/BR112020007858A2/pt active Search and Examination
- 2018-10-19 US US16/755,255 patent/US11352347B2/en active Active
- 2018-10-19 MX MX2020003400A patent/MX2020003400A/es unknown
- 2018-10-19 UA UAA202002979A patent/UA127738C2/uk unknown
- 2018-10-19 IL IL274045A patent/IL274045B2/en unknown
- 2018-10-19 ES ES18801102T patent/ES3016835T3/es active Active
- 2018-10-19 EP EP18801102.7A patent/EP3697779B1/en active Active
- 2018-10-19 SG SG11202003452XA patent/SG11202003452XA/en unknown
- 2018-10-19 JP JP2020542711A patent/JP7252963B2/ja active Active
- 2018-10-19 AU AU2018351494A patent/AU2018351494C1/en active Active
- 2018-10-19 CA CA3079558A patent/CA3079558A1/en active Pending
- 2018-10-19 EP EP25160825.3A patent/EP4574832A3/en active Pending
- 2018-10-19 NZ NZ763377A patent/NZ763377A/en unknown
- 2018-10-19 KR KR1020207013964A patent/KR102652642B1/ko active Active
- 2018-10-19 CN CN201880068207.9A patent/CN111344286A/zh active Pending
-
2020
- 2020-05-14 ZA ZA2020/02779A patent/ZA202002779B/en unknown
- 2020-05-20 CO CONC2020/0006193A patent/CO2020006193A2/es unknown
- 2020-07-13 MX MX2023010501A patent/MX2023010501A/es unknown
-
2022
- 2022-05-24 US US17/751,806 patent/US12269815B2/en active Active
-
2023
- 2023-01-23 JP JP2023007969A patent/JP2023061949A/ja active Pending
- 2023-12-08 AU AU2023278113A patent/AU2023278113B2/en active Active
-
2024
- 2024-10-17 US US18/918,855 patent/US20250145593A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286316A (en) | New micro-dystrophins and related method of use | |
| IL278080B (en) | Riluzole prodrugs and their use | |
| IL274276A (en) | CASZ preparations and methods of use | |
| ZA201905677B (en) | Glycan-interacting compounds and methods of use | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| PL3548033T3 (pl) | Związki i sposoby ich stosowania | |
| IL274045B1 (en) | Prodrugs of dantrolene and methods of using them | |
| SG11201803213XA (en) | Glycan-interacting compounds and methods of use | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| IL282482A (en) | Variants of protoxin-II and methods of use | |
| IL282508A (en) | Variants of protoxin-II and methods of use | |
| IL265761A (en) | Terlipressin compounds and methods of using them | |
| PT3661491T (pt) | 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica | |
| ZA201804228B (en) | Cftr regulators and methods of use thereof | |
| LT3072560T (lt) | Tramplinų sistemos ir jų gamybos bei naudojimo būdai | |
| GB201618414D0 (en) | Regulated cell lines and methods of use thereof | |
| IL260208A (en) | cftr regulators and methods of using them | |
| PT3397364T (pt) | Elementos estruturados e métodos de utilização | |
| ZA201804229B (en) | Cftr regulators and methods of use thereof | |
| IL261794A (en) | Preparations and methods for using them | |
| IL278575B1 (en) | Dantrolene formulations and methods of using them | |
| GB201709186D0 (en) | Construction block and methods of use | |
| GB201720516D0 (en) | Flakes and methods of forming flakes |